Pure Global AI
NCT06406608Recruiting

Patient-derived Organoid Drug Sensitivity Guided Treatment for Drug-resistant Recurrent Non-Small Cell Lung Cancer

Henan Cancer HospitalClinicalTrials.govother
Verified
Study focus
Disease/Condition
Non-small Cell Lung Cancer
Drug/Device/Intervention
Chemotherapy and targeted-therapy guided by organoid drug sensitivity test
Study type
Interventional
Intervention type
other
Sponsor & location
Primary sponsor
Henan Cancer Hospital
Location
Zhengzhou, China
Timeline & enrollment
Phase
N/A
Start date
Apr 16, 2024
End date
Jun 16, 2026
Enrollment
20 participants
Primary outcome

Objective Response Rate

Summary

This study aims to enroll non-small cell lung cancer patients who have undergone at least two
 rounds of standard treatment for drug resistance/recurrence. Patient-derived Organoid will be
 established, and drug sensitivity test will be conducted to intervene in the selection of
 clinical treatment plans. Efficacy evaluation and prognosis analysis will also be conducted.
 It is hoped that this study will provide a basis for the development of personalized
 treatment plans.

ICD-10 classifications
Secondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Middle lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06406608
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06406608 through Pure Global AI's free database. This phase not specified trial is sponsored by Henan Cancer Hospital and is currently Recruiting. The study focuses on Non-small Cell Lung Cancer. Target enrollment is 20 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.